Ozaki et al., 1959 - Google Patents
Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitroOzaki et al., 1959
- Document ID
- 4622378086365273090
- Author
- Ozaki M
- Weissbach H
- Ozaki A
- Witkop B
- Udenfriend S
- Publication year
- Publication venue
- Journal of Medicinal Chemistry
External Links
Snippet
Early studies on the inhibition of the enzyme, monoamine oxidase, suggested that certain sympathomimetic drugsowed their pharmacological activity to their ability to inhibit this enzyme. Drugs such as amphetamine, cocaine, and ephedrine were considered to …
- 239000002899 monoamine oxidase inhibitor 0 title abstract description 17
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N-C(=NH)-NH2), isourea (N=C(OH)-NH2), isothiourea (-N=C(SH)-NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ozaki et al. | Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro | |
| EP1326597B1 (en) | Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function | |
| JP2860285B2 (en) | Calcium receptor active composition | |
| Rothman et al. | Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin | |
| EP1203761B1 (en) | Calcium receptor-active compounds | |
| Stull et al. | Regulation of phosphorylase activation in skeletal muscle in vivo | |
| Kutt | Interactions of antiepileptic drugs | |
| US20070088074A1 (en) | Article of manufacture comprising aromatic amino acids isomers, analogs, or derivatives thereof to treat neurological disorders involving dysfunction of glutamatergic synaptic transmission | |
| CN1612732A (en) | Analgesics and methods of use | |
| US20030149082A1 (en) | Inhibitors of the anandamide transporter as analgesic agents | |
| JP2014077022A (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | |
| EP3403674A1 (en) | Pharmaceutical compositions for treating pain | |
| US9023788B2 (en) | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| Boura et al. | Peripheral anti-hypertensives: Ganglion and adrenergic neurone-blocking agents | |
| US20050136444A1 (en) | Treating neuropathic pain with neuropeptide FF receptor 2 agonists | |
| WO2002058687A2 (en) | Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics | |
| Kuntzman et al. | Monoamine oxidase inhibition by a series of compounds structurally related to bretylium and guanethidine | |
| US6239162B1 (en) | Method for treating depression | |
| Holmes | Medical use of psychostimulants: an overview | |
| AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
| JPS60500288A (en) | Esters of 3-(3-substituted amino-2-hydroxypropoxy)-4-substituted-1,2,5-thiazole derivatives | |
| Terleckyj et al. | The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. | |
| Varner et al. | Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity | |
| JPWO2007032536A1 (en) | Histamine H3 agonist as a therapeutic agent for lipid / sugar metabolic diseases | |
| Kopin | Metabolism of the catecholamines |